Bristol-Myers Squibb settles drug marketing allegations

Drug maker Bristol-Myers Squibb, along with a former subsidiary, has agreed to pay a $515 million settlement to shut down federal and state investigations of its drug marketing and pricing practices.

The investigations, which addressed practices in effect between 1994 and 2005, looked at a variety of allegations, including charges that the company marketed anti-psychotic drug Ability for uses not approved by the FDA, such as pediatric use and for treatment of dementia-related psychoses. The company is also accused of both price inflation and mis-reporting prices to Medicaid.

Investigators had also suggested that the pharmaceutical firm had paid what amounted to kickbacks, giving doctors large consulting fees and paying for high-toned travel packages to induce them to prescribe their medications. Former subsidiary Apothecon was also accused of such behavior.

To find out more about the investigation:
- read this Associated Press piece

Related Articles:
Pfizer sued over off-label use of Lipitor. Report
Schering fined $435 million for off-label marketing. Report
Lilly accused of promoting off-label Zyprexa use. Report
Cephalon takes heat for off-label narcotic promotion. Report
Study: Hospitalized kids get off-label drug prescriptions. Report

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.